TY - JOUR
T1 - Profilin1 E117G is a moderate risk factor for amyotrophic lateral sclerosis
AU - Fratta, Pietro
AU - Charnock, James
AU - Collins, Toby
AU - Devoy, Anny
AU - Howard, Robin
AU - Malaspina, Andrea
AU - Orrell, Richard
AU - Sidle, Katie
AU - Clarke, Jan
AU - Shoai, Maryam
AU - Lu, Ching Hua
AU - Hardy, John
AU - Plagnol, Vincent
AU - Fisher, Elizabeth M.C.
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Background Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are progressive neurodegenerative disorders that share significant clinical, pathological and genetic overlap and are considered to represent different ends of a common disease spectrum. Mutations in Profilin1 have recently been described as a rare cause of familial ALS. The PFN1 E117G missense variant has been described in familial and sporadic cases, and also found in controls, casting doubt on its pathogenicity. Interpretation of such variants represents a significant clinical-genetics challenge. Objective and results Here, we combine a screen of a new cohort of 383 ALS patients with multiple-sequence datasets to refine estimates of the ALS and FTD risk associated with PFN1 E117G. Together, our cohorts add up to 5118 ALS and FTD cases and 13 089 controls. We estimate a frequency of E117G of 0.11% in controls and 0.25% in cases. Estimated odds after population stratification is 2.44 (95% CI 1.048 to 8, Mantel- Haenszel test p=0.036). Conclusions Our results show an association between E117G and ALS, with a moderate effect size.
AB - Background Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are progressive neurodegenerative disorders that share significant clinical, pathological and genetic overlap and are considered to represent different ends of a common disease spectrum. Mutations in Profilin1 have recently been described as a rare cause of familial ALS. The PFN1 E117G missense variant has been described in familial and sporadic cases, and also found in controls, casting doubt on its pathogenicity. Interpretation of such variants represents a significant clinical-genetics challenge. Objective and results Here, we combine a screen of a new cohort of 383 ALS patients with multiple-sequence datasets to refine estimates of the ALS and FTD risk associated with PFN1 E117G. Together, our cohorts add up to 5118 ALS and FTD cases and 13 089 controls. We estimate a frequency of E117G of 0.11% in controls and 0.25% in cases. Estimated odds after population stratification is 2.44 (95% CI 1.048 to 8, Mantel- Haenszel test p=0.036). Conclusions Our results show an association between E117G and ALS, with a moderate effect size.
UR - http://www.scopus.com/inward/record.url?scp=84898604449&partnerID=8YFLogxK
U2 - 10.1136/jnnp-2013-306761
DO - 10.1136/jnnp-2013-306761
M3 - Article
C2 - 24309268
AN - SCOPUS:84898604449
SN - 0022-3050
VL - 85
SP - 506
EP - 508
JO - Journal of Neurology, Neurosurgery and Psychiatry
JF - Journal of Neurology, Neurosurgery and Psychiatry
IS - 5
ER -